Biology and genetics

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Colombo M et al. Oncotarget. 2016 Jul 24. doi: 10.18632/oncotarget.10820. [Epub ahead of print]. HLA polymorphism and risk of multiple myeloma. Beksac M et al. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T et…

General

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…

Complications of myeloma and its treatments

Assessment of Bone Fragility in Patients with Multiple Myeloma Using QCT-Based Finite Element Modelling. Campbell GM et al. J Bone Miner Res. 2016 Jul 25. doi: 10.1002/jbmr.2924. [Epub ahead of print]. Intracranial Involvement by Plasma Cell Neoplasms. Wilberger AC et al. Am J Clin Pathol. 2016 Jul 24. pii: aqw058. [Epub ahead of print]. Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient…

Current treatments

Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print]. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print]. Peripheral blood stem cells collection…

New genetic clues help explain inherited predisposition to myeloma

A study published recently in Nature Communications has identified eight new genetic risk loci for myeloma, providing further insights into the genetic and biological basis of its predisposition. The research, performed at The Institute of Cancer Research (ICR) and part funded by Myeloma UK involved a meta-analysis of pooled data from several independent genome-wide association…

Diagnostic tests and prognostic indicators

Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Muchtar E et al. Hematol Oncol. 2016 Jun 21. doi: 10.1002/hon.2303. [Epub ahead of print]. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. D’Souza A et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14170. [Epub ahead of print].…

Related conditions

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications. Hemminki K et al. Sci Rep. 2016 Jun 22;6:28500. doi: 10.1038/srep28500. Next generation sequencing identifies a transcriptional profile that segues with genomic alterations in Waldenström macroglobulinemia. Hunter ZR et al. Blood. 2016 Jun 14. pii: blood-2016-03-708263. [Epub ahead of print]. Short- and long-term outcomes…

Emerging treatments

Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print]. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii:…

Biology and genetics

HIF-1α and rapamycin act as genosuppressant in multiple myeloma cells upon genotoxic stress. Coudre C et al. Cell Cycle. 2016 Jun 24:0. [Epub ahead of print]. CA-125 secreting IgG kappa Multiple Myeloma (MM). Boota M et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print]. To B(ortezomib) or Not to B: The Stroma’s the Thing. Krem MM et al. J Pathol. 2016 Jun 24.…